TP53 and acute lymphoblastic leukemia: At the same time, such inhibitors will almost exclusively be beneficial for patients carrying wild-type p53, such as KMT2A-rearranged infant ALL patients, where the incidence of p53 mutations is rare and only occurs in ~4% of the cases [10,11].